

## SC4

### Pharmaceutical Co-Crystals: Screening, Properties and Applications

Fritz Blatter\*, Heike Süss\*, Rainer Mahlkecht#, Georgios Imanidis#, and Rolf Hilfiker\*

\*Solvias AG,

#Pharmazentrum der Universität Basel

Co-crystals with small molecules have recently gained the attention of the pharmaceutical industry since in addition to pharmaceutical salts, co-crystals represent a class of solids which can open new possibilities for chemical and pharmaceutical development. In some special cases, co-crystal systems may be the preferred solid-state material to be developed. Solvias has established a database for high throughput screening of co-crystals with more than 30 different co-crystal formers that are pharmaceutically acceptable from the regulatory point of view. The screening approach of Solvias will be briefly outlined, and the latest results on S-ibuprofen will be presented. In addition, selected case studies such as carbamazepine and itraconazole, which are drug substances that are known to form co-crystals with other small molecules will be discussed.